Acceleron Pharma to Participate in Two Healthcare Investor Conferences in May

CAMBRIDGE, Mass.--()--Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body’s ability to rebuild and repair its own cells and tissues, today announced that senior management will participate in two upcoming healthcare investor conferences in May.

Conference Details:

Event: Deutsche Bank 41st Annual Health Care Conference
Date/Time: May 5, 2016 at 10:00 a.m. EDT
Location: The Intercontinental Hotel, Boston, MA
Event: 2016 UBS Global Healthcare Conference
Date/Time: May 23, 2016 at 3:00 p.m. EDT
Location: Grand Hyatt, New York, NY

Live audio webcasts for both conferences will be available on the "Events and Presentations" page in the Investors section on the Company's website ( A replay of the webcasts will also be available on Acceleron's website.

About Acceleron

Acceleron discovers and develops novel therapies to treat a wide range of rare diseases. Its pioneering research platform leverages the powerful biology behind the body’s ability to rebuild and repair its own cells and tissues. This innovative approach to drug discovery has generated four therapeutic candidates currently in clinical trials. The Company’s lead therapeutic candidate, luspatercept, is being evaluated in Phase 3 studies for the treatment of the hematologic diseases myelodysplastic syndromes (MDS) and beta-thalassemia under a global partnership with Celgene Corp. Acceleron is also advancing clinical programs in the fields of oncology and neuromuscular diseases and has a comprehensive preclinical research effort targeting fibrotic and other serious diseases.

For more information, please visit Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.


Acceleron Pharma Inc.
Todd James, IRC, 617-649-9393
Senior Director, Investor Relations and Corporate Communications
BMC Communications LLC
Brad Miles, 646-513-3125

Recent Stories

RSS feed for Acceleron Pharma

Acceleron Pharma